Sabby Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Sabby Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-11,433	Closed	-$166K	–	133
2018 Q4	$166K	Buy	11,433 +3,485	+44%	+$142K	0.04%	76
2018 Q3	$556K	Sell	7,948 -6,682	-46%	-$507K	0.07%	71
2018 Q2	$1.09M	Buy	+14,630	New	+$1.3M	0.17%	55
2018 Q1	–	Sell	-3,571	Closed	-$612K	–	188
2017 Q4	$461K	Sell	3,571 -3,390	-49%	-$318K	0.04%	104
2017 Q3	$473K	Buy	6,961 +2,786	+67%	+$227K	0.03%	103
2017 Q2	$395K	Sell	4,175 -230	-5%	-$26.4K	0.03%	156
2017 Q1	$632K	Sell	4,405 -1,919	-30%	-$274K	0.03%	165
2016 Q4	$801K	Buy	+6,324	New	+$880K	0.05%	161
2015 Q3	–	Sell	-1,167	Closed	-$738K	–	411
2015 Q2	$738K	Sell	1,167 -142	-11%	-$75.5K	0.03%	236
2015 Q1	$673K	Buy	+1,309	New	+$660K	0.03%	219
2014 Q1	–	Sell	-533	Closed	-$620K	–	276
2013 Q4	$530K	Buy	+533	New	+$551K	0.03%	148
2013 Q3	–	Sell	-859	Closed	-$939K	–	231
2013 Q2	$939K	Buy	+859	New	+$957K	0.06%	122

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management's VIRX Position: Q1 2019 in Review

Sabby Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2019, closing a stake of 11,433 shares — an estimated $166K sold.

Sabby Management first reported a position in VIRX in Q2 2013 and held it in 12 quarters. The position peaked at $1.09M in Q2 2018. 44 funds tracked by Wall St. Rank hold VIRX as of Q1 2019.

Sabby Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Sabby Management sold 11,433 Viracta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $166K.
Sabby Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
Sabby Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.09M in Q2 2018.
44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.